Skip to main content

LIDDS patent covering the NanoZolid® production process granted in Russia and Australia

Written by Customer Service on . Posted in Public Companies.

UPPSALA, SWEDEN – LIDDS AB (publ) announces today that its most recent patent family on the NanoZolid® production process, and hence achieved pharmaceutical products, has been granted in Russia and Australia. The patent provides protection until 2037 in these markets.

“This patent is central to LIDDS and significantly broadens our patent protection. The product aspect of the patent improves the ability to detect infringement and it further strengthens our already strong IP portfolio. The decision from the patent authorities in Russia and Australia gives us important protection for our production process, and hence the pharmaceutical products that we derive from this process,” said Nina Herne, CEO of LIDDS.

Recently, LIDDS has received patent approvals in Russia (patent no. 275334) and Australia (patent no. 201734489). The invention covering process and products based on the NanoZolid® technology provides protection until 2037. Furthermore, the patent protects all pharmaceutical products obtained with the process described in the patent. During 2021 the same patent family has also received approvals in India, South Africa and Singapore. The patent and a related divisional patent are already approved in the US as previously communicated.

 For more information, please contact:

Nina Herne, CEO, +46 (0)70 714 7457, e-mail: nina.herne@liddspharma.com

The information was submitted for publication, through the agency of the aforementioned contact person, on September 28 16.00 CET.

LIDDS AB (publ) is a Swedish-based pharmaceutical company focusing on a unique proprietary drug delivery technology: NanoZolid®. NanoZolid® is a clinically validated drug development technology and superior in its ability to provide a controlled and sustained release of active drug substances for up to six months. LIDDS has licensing agreements where NanoZolid® is combined with antiandrogens and in-house development projects in clinical and preclinical phase for cytostatics and immunoactive agents. LIDDS shares are listed on Nasdaq First North Growth Market ( ticker LIDDS). Redeye AB is the Certified Adviser to LIDDS (+46 (0) 8 121 576 90, email: certifiedadviser@redeye.se) For more information, please visit www.liddspharma.com.

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.